The Gynecologic Oncology Group experience in ovarian cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 1, 1999, Pages

  McGuire, W P ^c   Brady, M F ^a   Ozols, R F ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c NONE   (United States)

Author keywords

Gynecologic Oncology Group (GOG) protocols; New drugs; Platinum; Taxanes

Indexed keywords

ACIVICIN; AMINOTHIADIAZOLE; AMSACRINE; CISPLATIN; CYCLOPHOSPHAMIDE; DIANHYDROGALACTITOL; DIDEMNIN B; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ECHINOMYCIN; EDATREXATE; ETOPOSIDE; FAZARABINE; GEMCITABINE; IFOSFAMIDE; MAYTANSINE; MERBARONE; OXANTHRAZOLE; PIPERAZINEDIONE; RAZOXANE; TAXANE DERIVATIVE; TOPOTECAN; TRIAZINATE; VINBLASTINE;

ADULT; AGED; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DNA REPAIR; DNA SYNTHESIS INHIBITION; DRUG EFFECT; DRUG EFFICACY; FEMALE; GYNECOLOGIC CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0032908688     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0923-7534(20)31481-2     Document Type: Conference Paper

References (55)

1. Young RC, Walton LA, Ellenberg SS et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021-7.
2. Young RC, Brady MF, Nieberg RM et al. Randomized clinical trial of adjuvant treatment of women with early (FIGO I-IIA high risk) ovarian cancer - GOG #95, Int Gyn Cancer Soc 1997.
3. Omura GA, Bundy BN, Berek JS et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A. Gynecologic Oncology Group study. J Clin Oncol 1989; 7(4): 457-65.
4. Alberts DS, Lui PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335(26): 1950-5.
5. Markman M, Bundy B, Benda J et al. Randomized phase 3 study of intravenous (IV) cisplatin (cis)/ paclitaxel (PAC) versus moderately high dose IV carboplatin followed by IV PAC and intraperitoneal (IP) cis in optimal residual ovarian cancer: An Intergroup Trial (GOG, SWOG, ECOG). Proc of Am Soc Clin Oncol 1998; 17, A:1392.
6. Creasman WT, Omura GA, Brady MF et al. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus calmette-guerin in patients with suboptimal stage III and IV ovarian cancer: A Gynecologic Oncology Group study. Gynecol. Oncol. 1990; 39: 239-43.
7. McGuire WP, Hoskins WJ, Brady MF et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 1995; 13(7): 1589-99.
8. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage HI and stage IV ovarian cancer. N Engl J Med 1996; 334(1): 1-6.
9. Muggia FM, Braly PS, Brady MF et al. A Phase III randomized study of cisplatin versus paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 1998; submitted.
10. Thigpen JT, Blessing JA, Arseneau JC, Homseley, HD. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or re-current carcinoma of the ovary. A Gynecologic Oncology Group study. Am J Clin Oncol Cancer Clin Trials 1984; 7: 261-3.
11. Thigpen JT, Shingleton H, Homseley H et al. cis-Dichlorodiammine platinum (II) in the treatment of gynecologic malignancies: Phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep 1979; 63(9-10): 1549-55.
12. Slayton RE, Creasman WT, Petty W et al. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary. A Gynecologic Oncology Group study. Cancer Treat Rep 1979; 63(11-12):2089-92.
13. Stehman FB, Blom J, Blessing JA et al Phase II trial of galactitol 1,2:5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: A Gynecologic Oncology Group study. Gynecol Oncol 1983; 15: 381-90.
14. Arseneau JC, Bundy B, Homesley H, Beecham I. Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary: A Gynecologic Oncology Group study. Invest New Drugs 1983; 1:185-8.
15. Conroy JF, Blessing JA, Kessinger A, Homesley HD. Phase II trial of razoxane in the management of recurrent adenocarcinoma of the ovary: A Gynecologic Oncology Group study. Cancer Treat Rep 1984; 68(2): 439-40.
16. Thigpen JT, Ehrlich CE, Creasman WT et al. Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study. Am J Clin Oncol Cancer Clin Trials 1983; 6: 273-5.
17. Slavik M, Muss H, Blessing JA, Delgado G. Phase II clinical study of yoshi864 in epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Cancer Treat Rep 1982; 66(9): 1775-7.
18. Markman M, Iseminger KA, Hatch KD et al. Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group ancillary report. Gynecol Oncol 1996; 62: 4-6.
19. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991; 68: 269-71.
20. Muss HB, Slavik M, Bundy B et al. A Phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol Cancer Clin Trials 1994; 7: 257-60.
21. Muss HB, Asbury R, Bundy B et al. Mitoxantrone (NSC-301739) in patients with advanced ovarian carcinoma: A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol Cancer Clin Trials 1984; 7: 737-9.
22. Slayton RE, Blessing JA, Sutton GP et al. Phase II clinical trial of diaziquone in the treatment of patients with epithelial ovarian cancer: A Gynecologic Oncology Group study. Cancer Treat Rep 1986; 70(2): 309-10.
23. McGuire WP, Blessing JA, DiSaia PJ, Buchsbaum HJ. Phase II trial of acivivin in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study. Invest New Drugs 1986; 4: 49-52.
24. Asbury RF, Wilson J, Blessing JA et al. Aminothiadiazole (NSC 4728) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol Cancer Clin Trials 1986; 9(4): 334-6.
25. Malfetano J, Beecham JB, Bundy BN, Hatch KD. A phase II trial of medroxyprogesterone acetate in epithelial ovarian cancers: A Gynecologic Oncology Group study. Am J Clin Oncol Cancer Clin Trials 1993; 16(2): 149-51.
26. Muss H, Bundy BN, DiSaia PJ, Twiggs LB. Teniposide in epithelial ovarian carcinoma: A phase II trial of the Gynecologic Oncology Group. Cancer Treat Rep 1986; 70(10): 1231-2.
27. McGuire WP, Blessing JA, Berman ML. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: A Gynecologic Oncology Group study. Invest New Drugs 1989; 7: 333-6.
28. Sutton GP, Blessing JA, Homesley HD et al. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1989; 7(11): 1672-6.
29. McGuire WP, Blessing JA, Berek JS, Munoz A. Phase II study of N-methylformanide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group study. Invest New Drugs 1990; 8: 191-4.
30. Muss HB, Blessing JA, Baker VV et al. Echinomycin (NSC 526417) in advanced ovarian cancer: A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol Cancer Clin Trials 1990; 13(4): 299-301.
31. Malfetano JH, Blessing JA, Adelson, MD. A phase II trial of gallium nitrate (NSC 15200) in previously treated ovarian carcinoma: A Gynecologic Oncology Group Study. Am J Clin Oncol Cancer Clin Trials 1991; 14(4): 349-51.
32. Sutton GP, Blessing JA, Adelson MD, Hanjani P. Phase II trial of vinblastine in advanced ovarian carcinoma: A Gynecologic Oncology Group Study. Invest New Drugs 1990; 8: 377-9.
33. Miller DS, Brady MF, Barrett RJ. A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Am J Clin Oncol Cancer Clin Trials 1992; 15(2): 125-8.
34. Asbury RF, Blessing JA, Look KY et al. A Gynecologic Oncology Group phase II study of amonafide (NSC 308847) in epithelial ovarian cancer. Am J Clin Oncol Cancer Clin Trials 1993; 16(6): 529-31.
35. Malfetano JH, Blessing JA, Jacobs AJ. A phase II trial of didemnin B (NSC 335319) in patients with previously treated epithelial ovarian cancer: A Gynecologic Oncology Group study. Am J Clin Oncol Cancer Clin Trials 1993; 16(1): 47-9.
36. Thigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 1994; 12(9): 1748-53.
37. Manetta A, Blessing JA, Look KY. A phase II study of fazarabine in patients with advanced ovarian cancer. A Gynecologic Oncology Group study. Am J Clin Oncol Cancer Clin Trials 1995; 18(2) 156-7.
38. Look KY, Blessing JA, Muss HB, DeGeest K. 5-Fluorouracil and low-dose leucovorin in the treatment of recurrent epithelial ovarian carcinoma: A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol Cancer Clin Trials 1992; 15(6): 494-6.
39. Look KY, Muss HB, Blessing JA, Morris M. A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Am J Clin Oncol Cancer Clin Trials 1995; 18(1): 19-22.
40. Look KY, Blessing JA, Adelson MD et at. A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Am J Clin Oncol Cancer Clin Trials 1996; 19(1): 7-9.
41. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant ovarian carcinoma. A Gynecologic Oncology Group study. J Clin Oncol 1998; 16(2): 405-10.
42. Broun ER, Iseminger KA, Bookman M. A phase II trial of edatrexate in previously treated ovarian cancer: A Gynecologic Oncology Group study. Am J Clin Oncol Cancer Clin Trials 1995; 18(2): 164-6.
43. Manetta A, Blessing JA, Hurteau JA. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol 1998; 68: 45-6.
44. Markman M, Blessing JA, Moore D et al. Altretamine (Hexamethyl-melamine) in platinum-resistant and platinum-refractory ovarian cancer: A Gynecologic Oncology Group phase II trial. Gynecol Oncol 1998; 69: 226-9.
45. Muggia FM, Blessing J, Homesley H, Srorsky JI. Tomudex: Minimal activity in previously treated epithelial ovarian cancer: A Gynecology Oncology Group (GOG) study. Proc Am Soc Clin Oncol 15, A: 837 1996.
46. Bookman MA, McGuire WP, Kilpatrick D et al. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996; 14(6): 1895-1902.
47. O'Reilly S, Fleming GF, Baker SD et al. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study. J Clin Oncol 1997; 15(1): 177-186.
48. The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus Cyclophosphamide doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis J Clin Oncol 1991; 9(9): 1668-74.
49. Underhill C, Parnis FX, Highley M et al. A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 1996; 15: A795.
50. Lund B, Hansen OP, Neijt JP et al. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs 1995;6(Suppl 6):61-2.
51. Millward MJ, Rischin D, Toner GC et al. Activity of gemcitabine in ovarian cancer patients resistant to paclitaxel. Proc Am Soc Clin Oncol 1995;14: A776.
52. Kaufman M, Bauknecht T, Jonat W et al. Gemcitabine (GEM) in cis-platin-resistant ovarian cancer, Proc Am Soc Clin Oncol 1995; 14: A758.
53. Lund B, Hansen OP, Theilade K et al. Phase II study of gemcitabine (2',2'-diflourodeoxycytidine) in previously treated ovarian cancer patients. J Nat Can Inst 1994; 86(20): 1530-3.
54. Muggia FM, Hainsworth JD, Jeffers S et al. A phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15(3): 987-93.
55. Gordon AN, Hainsworth J, Moore M et al. Doxil (Doxorubicin HCL liposome injection) in the treatment of patients with refractory advanced epithelial ovarian carcinoma-results of an interim analysis. Proc Am Soc Clin Oncol 1998; 17: A1345.